CAJ | 학술논문

目的：观察吉非替尼治疗晚期非小细胞肺癌（ NSCLC）的疗效和毒副作用。方法对化疗失败的68例晚期非小细胞肺癌患者进行口服吉非替尼治疗，每日口服250 mg/次，每日1次，1个月之后观察疗效。结果 CR 3例，PR 21例，SD 27例，PD 17例。治疗有效率为35．29％，疾病控制率为75．00％。女性患者的疗效明显优于男性患者，腺癌患者疗效明显优于鳞癌患者的疗效，差异均有统计学意义，P＜0．05；疗效与是否采取化疗和有无吸烟史无关（P＞0．05）；不良反应：皮疹40例，腹泻23例，恶心18例，皮肤干燥11例，经对症处理，均可缓解。结论吉非替尼对晚期非小细胞肺癌疗效较好，其中对于女性以及腺癌的患者治疗效果更好，值得在临床进行深入研究。
목적：관찰길비체니치료만기비소세포폐암（ NSCLC）적료효화독부작용。방법대화료실패적68례만기비소세포폐암환자진행구복길비체니치료，매일구복250 mg/차，매일1차，1개월지후관찰료효。결과 CR 3례，PR 21례，SD 27례，PD 17례。치료유효솔위35．29％，질병공제솔위75．00％。녀성환자적료효명현우우남성환자，선암환자료효명현우우린암환자적료효，차이균유통계학의의，P＜0．05；료효여시부채취화료화유무흡연사무관（P＞0．05）；불량반응：피진40례，복사23례，악심18례，피부간조11례，경대증처리，균가완해。결론길비체니대만기비소세포폐암료효교호，기중대우녀성이급선암적환자치료효과경호，치득재림상진행심입연구。
Objective To evaluate the efficacy and side effects of gefitinib for advanced non-small cell lung cancer (NSCLC).Methods 68 cases of advanced non-small cell lung cancer patients who failed chemotherapy were treated with ge-fitinib,oral administration of 250 mg/times a day,efficacy was observed after a month .Results CR 3 cases,PR 21 cases,SD 27 cases,PD 17 cases.The effective rate was 35.29%,disease control rate was 75.00%.Efficacy of female patients was significantly better than that of male patients ,the efficacy of cancer patients were significantly better than patients with squamous cell carcino -ma,the differences were statistically significant ,P<0.05;efficacy was not related with chemotherapy and smoking history ( P>0.05);adverse reactions:skin rash in 40 cases,23 cases of diarrhea,nausea in 18 cases,11 cases of dry skin,they can be allevia-ted with symptomatic treatment .Conclusion Gefitinib for advanced non-small cell lung cancer is effective , and it has better effect for women and adenocarcinoma ,it is worthy of further study in clinical practice .